SHIRE PLC: Director/PDMR Share Dealings
Director/PDMR Share Dealings
March 4, 2013 - Shire plc (LSE: SHP, NASDAQ: SHPG), (the `Company') announces that on February 28, 2013 the following Persons Discharging Managerial Responsibility (`PDMRs') were granted awards under the Shire Portfolio Share Plan (`PSP').
Stock Appreciation Right Awards (`SAR Awards') under Part A of the PSP
SAR Awards will normally vest after three years, subject to any performance conditions being satisfied. No consideration is payable for these awards.
Type of Security(1) No of Ordinary Exercise price
Shares/ADSs
Flemming Ornskov(2) ADSs 45,601 $95.04
Graham Hetherington(2) Ordinary Shares 66,708 £20.88
Jeffrey Jonas ADSs 6,291 $95.04
Tatjana May Ordinary Shares 22,489 £20.88
Performance Share Awards (`PSA Awards') under Part B of the PSP
PSA Awards will normally vest after three years, subject to any performance conditions being satisfied. No consideration is payable for these awards.
Type of Security(1) No of Ordinary
Shares/ADSs
Flemming Ornskov(2) ADSs 34,201
Graham Hetherington(2) Ordinary Shares 48,919
Jeffrey Jonas ADSs 4,529
Tatjana May Ordinary Shares 16,192
(1). One ADS is equal to three Shire plc ordinary shares of 5 pence each.
(2). Vesting of awards granted to Executive Directors is subject to performance conditions.
Release of PSA Awards
The Company also announces that on March 1, 2013 the following ordinary shares and ADSs were released in connection with PSA Awards granted on 1 March 2010 under Part B of the PSP. The Company was notified today that sufficient ordinary shares and ADSs were sold on March 1, 2013 to satisfy the relevant personal tax liabilities of each PDMR.
Number of ADSs Number of ADSs
released(4) sold(5)
Angus Russell(3) 75,033 30,342
Sylvie Gregoire 15,220 5,339
Jeffrey Jonas 2,115 633
Number of Number of
Ordinary Shares Ordinary Shares
released(4) sold(6)
Graham Hetherington(3) 100,314 52,594
Tatjana May 28,410 14,896
(3). The PSA Awards granted in 2010 to Angus Russell and Graham Hetherington were subject to performance conditions measured over the performance period 2010 to 2012. Based on the performance conditions, 100% of the PSA Awards vested.
(4). In accordance with the rules of the PSP, the vested PSA awards have been increased to reflect the dividends paid by the Company in the period from the grant date to the vesting date.
(5). ADSs were sold on the NASDAQ at an average sale price of $94.28028 each.
(6). Ordinary shares were sold on the London Stock Exchange at an average sale price of £20.76842 each.
This notification is made to satisfy the Company's obligations under 3.1.4(R) (1)(a) of the Disclosure and Transparency Rules.
Tony Guthrie Deputy Company Secretary
For further information please contact:
Investor Relations
Eric Rojas erojas@shire.com +1 781 482 0999
Sarah Elton-Farr seltonfarr@shire.com +44 1256 894157
Notes to editors
Shire enables people with life-altering conditions to lead better lives.
Through our deep understanding of patients' needs, we develop and provide healthcare in the areas of:
* Behavioral Health and Gastro Intestinal conditions
* Rare Diseases
* Regenerative Medicine
as well as other symptomatic conditions treated by specialist physicians.
We aspire to imagine and lead the future of healthcare, creating value for
patients, physicians, policymakers, payors and our shareholders.
Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PX
Press Release
www.shire.com
END
-0- Mar/04/2013 16:06 GMT
Rate this Page